<DOC>
	<DOCNO>NCT01774825</DOCNO>
	<brief_summary>After 2 week run-in period , subject randomize either IQP-CL-101 match placebo . Over 8 week , subject monitor improvement IBS symptom</brief_summary>
	<brief_title>IQP-CL-101 IBS Management</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Fulfils RomeIII criterion IBS diagnosis Females ' agreement use appropriate birth control method active study period female childbearing potential Subject declares write his/her consent participate , understand requirement study willing comply Known sensitivity ingredient IQPCL101 Clinically relevant abnormality colonoscopy within last 2 year prior randomization Other cause IBS symptom inflammatory bowel disease ( IBD ) , microscopic colitis , celiac disease , history abdominal obstruction , cholecystitis , pancreatitis , ileus , gastrointestinal bleeding Use medication could influence GI function ( e.g . antibiotic , laxative , opioids , glucocorticoid , anticholinergic , antidiarrheal ) within 1 month prior randomization Clinically relevant excursion safety parameter Any condition deem relevant investigator ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>IBS</keyword>
</DOC>